Combination treatment for the regenerative therapy of type 1 diabetes mellitus patients
AssigneeLevicure Ltd.
InventorShmuel Boris Levit
Life of this patent
Estimating the term…
Abstract
This invention applies to the field of medicine, namely to endocrinology, and intended for the treatment of type 1 diabetes mellitus. The invention proposes a combination, containing a Dipeptidyl peptidase-4 (DPP-4) inhibitors, a proton pump inhibitors (PPI), and gamma-aminobutyric acid or a gamma-aminobutyric acid receptor agonists. This unique combination of medications and specific dosage of drugs leads to the regeneration (recovery) of the β-cells of the pancreas, which is presented by a dramatic reduction of insulin requirements up to a total insulin discontinuation in some persons.
Claims2
An orally-administrated combination for use in regenerative therapy in patients with type 1 diabetes mellitus, characterized in that it consists of:
- a medication belonging to the group of dipeptidyl peptidase (DPP-4) inhibitors and contains a therapeutically effective amount of DPP-4 inhibitor, which makes up to a daily dose of 25 to 100 mg in average;
- a medication of the proton pump inhibitor group (PPI) which contains a therapeutically effective amount of PPI, comprising a daily dose of 10 to 40 mg;
- and a gamma-aminobutyric acid preparation (GABA) or gamma amino butyric acid receptor agonist, usually given trice daily, each dose containing a therapeutically effective amount of GABA or a GABA receptor agonist of 125 to 500 mg.
Dependencies are inferred from the claim text.